2023
Differential cardiopulmonary haemodynamic phenotypes in PASC-related exercise intolerance
Kahn P, Joseph P, Heerdt P, Singh I. Differential cardiopulmonary haemodynamic phenotypes in PASC-related exercise intolerance. ERJ Open Research 2023, 10: 00714-2023. PMID: 38348243, PMCID: PMC10860209, DOI: 10.1183/23120541.00714-2023.Peer-Reviewed Original ResearchInvasive cardiopulmonary exercise testingRight heart catheterizationPASC patientsExertional intoleranceCardiac outputPulmonary artery wedge pressurePeak VO 2Supranormal cardiac outputPeak exercise capacityCardiopulmonary exercise testingMaximal voluntary ventilationPost-acute sequelaeBody mass indexSystemic oxygen extractionMild acute illnessSARS-CoV-2Exercise hemodynamicsHFpEF patientsHFpEF phenotypeHeart catheterizationWedge pressureAcute illnessExercise capacityExercise testingHemodynamic abnormalities
2016
Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure
Malhotra R, Dhakal B, Eisman A, Pappagianopoulos P, Dress A, Weiner R, Baggish A, Semigran M, Lewis G. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure. Circulation Heart Failure 2016, 9 PMID: 27301469, PMCID: PMC4911900, DOI: 10.1161/circheartfailure.115.003011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntihypertensive AgentsArterial PressureCase-Control StudiesDouble-Blind MethodExercise TestExercise ToleranceFemaleHeart FailureHumansHypertension, PulmonaryKaplan-Meier EstimateLinear ModelsMaleMiddle AgedModels, CardiovascularMultivariate AnalysisPhosphodiesterase 5 InhibitorsPredictive Value of TestsProportional Hazards ModelsProspective StudiesPulmonary ArteryRisk AssessmentRisk FactorsSeverity of Illness IndexSildenafil CitrateStroke VolumeTime FactorsTreatment OutcomeVascular StiffnessVasodilator AgentsVentricular Function, RightConceptsPV distensibilityPulmonary arterial hypertensionReduced ejection fractionHeart failureEjection fractionExercise capacityArterial hypertensionHF patientsRight ventricular ejection fractionPulmonary artery wedge pressureReduced ejection fraction groupPulmonary arterial hypertension groupFirst-pass radionuclide ventriculographyPulmonary vasodilator therapyRV systolic functionVentricular ejection fractionLeft heart failurePulmonary artery pressureEjection fraction groupPulmonary hypertension severityRight ventricular performanceArterial hypertension groupInvasive hemodynamic monitoringWeeks of treatmentPredictors of peak VO2
2014
An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease
Klings E, Machado R, Barst R, Morris C, Mubarak K, Gordeuk V, Kato G, Ataga K, Gibbs J, Castro O, Rosenzweig E, Sood N, Hsu L, Wilson K, Telen M, Decastro L, Krishnamurti L, Steinberg M, Badesch D, Gladwin M. An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal Of Respiratory And Critical Care Medicine 2014, 189: 727-740. PMID: 24628312, PMCID: PMC3983842, DOI: 10.1164/rccm.201401-0065st.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemia, Sickle CellAnticoagulantsAntihypertensive AgentsAntisickling AgentsCardiac CatheterizationDecision Support TechniquesEchocardiography, DopplerErythrocyte TransfusionHumansHydroxyureaHypertension, PulmonaryPhosphodiesterase 5 InhibitorsRisk AssessmentSeverity of Illness IndexConceptsRight heart catheterizationTricuspid regurgitant velocitySickle cell diseasePulmonary vascular resistancePulmonary hypertensionManagement of patientsEvidence-based recommendationsStrong recommendationsWedge pressureVascular resistanceRisk stratificationWeak recommendationCell diseaseMortality riskOfficial American Thoracic Society Clinical Practice GuidelineSerum N-terminal pro-brain natriuretic peptide (NT-proBNP) levelsN-terminal pro-brain natriuretic peptide levelsElevated pulmonary artery wedge pressureNormal pulmonary capillary wedge pressurePro-brain natriuretic peptide levelsElevated tricuspid regurgitant velocityLow pulmonary vascular resistanceNT-pro-BNP levelsPhosphodiesterase-5 inhibitor therapyPulmonary artery wedge pressure
1988
Dynamics of early and late left ventricular filling determined by Doppler two-dimensional echocardiography during percutaneous transluminal coronary angioplasty
Bowman L, Cleman M, Cabin H, Zaret B, Jaffe C. Dynamics of early and late left ventricular filling determined by Doppler two-dimensional echocardiography during percutaneous transluminal coronary angioplasty. The American Journal Of Cardiology 1988, 61: 541-545. PMID: 2964191, DOI: 10.1016/0002-9149(88)90761-8.Peer-Reviewed Original ResearchConceptsPercutaneous transluminal coronary angioplastyEarly peak filling ratePeak filling rateLate filling ratioTransluminal coronary angioplastyAtrial stroke volumeLeft ventricular fillingBalloon inflationVentricular fillingCoronary angioplastyStroke volumeMean pulmonary artery wedge pressureDominant right coronary arteryPulmonary artery wedge pressureLate ventricular fillingRight coronary arteryGlobal systolic functionTwo-dimensional echocardiographyInfluence of ischemiaFilling rateWedge pressureLeft circumflexSystolic functionCoronary occlusionBalloon deflation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply